Different intracellular compartmentalization of TA and ΔNp73 in non-small cell lung cancer

International Journal of Oncology

Volumn 34, Issue 2, 2009, Pages 449-456

  Di Vinci, Angela ^a   Sessa, Fausto ^b   Casciano, Ida ^a   Banelli, Barbara ^a   Franzi, Francesca ^b   Brigati, Claudio ^a   Allemanni, Giorgio ^a   Russo, Patrizia ^a   Dominioni, Lorenzo ^b   Romani, Massimo ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Lung cancer; Methylation; p73

Indexed keywords

PROTEIN P53; PROTEIN P73;

APOPTOSIS; ARTICLE; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MALE; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DNA METHYLATION; DNA PRIMERS; DNA, NEOPLASM; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 64549155365     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000169     Document Type: Article

References (41)

1. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F and Caput D: Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90: 809-819, 1997.
2. Jost CA, Marin MC and Kaelin WG Jr: p73 is a human p53-related protein that can induce apoptosis. Nature 389: 191-194, 1997.
3. Melino G, De Laurenzi V and Vousden KH: p73: Friend or foe in tumorigenesis. Nat Rev Cancer 2: 605-615, 2002.
4. Stiewe T, Zimmermann S, Frilling A, Esche H and Putzer BM: Transactivation-deficient ΔTA-p73 acts as an oncogene. Cancer Res 65: 3590-3602, 2002.
5. Grob TJ, Novak U, Maisse C, Barcaroli D, Luthi AU, Pirnia F, Hugli B, Graber HU, De Laurenzi V, Fey MF, Melino G and Tobler A: Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ 8: 1213-1223, 2001.
6. Kartasheva NN, Contente A, Lenz-Stoppler C, Roth J and Dobbelstein M: p53 induces the expression of its antagonist p73 Delta N, establishing an autoregulatory feedback loop. Oncogene 21: 4715-4727, 2002.
7. Nakagawa T, Takahashi M, Ozaki T, Watanabe K, Todo S, Mizuguchi H, Hayakawa T and Nakagawara A: Autoinhibitory regulation of p73 by deltaNp73 to modulate cell survival and death through a p73-specific target element within the deltaNp73 promoter. Mol Cell Biol 22: 2575-2585, 2002.
8. Zaika A, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M, Chalas E and Moll UM: ΔNp73, a dominant-negative inhibitor of wild-type 53 and TAp73, is upregulated in human tumors. J Exp Med 196: 765-780, 2002.
9. Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T and Ikawa S: Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res 62: 636-641, 2002.
10. Kovalev S, Marchenko N, Swendeman S, LaQuaglia M and Moll UM: Expression level, allelic origin, and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines. Cell Growth Differ 9: 897-903, 1998.
11. Tokuchi Y, Hashimoto T, Kobayashi Y, Hayashi M, Nishida K, Hayashi S, Imai K, Nakachi K, Ishikawa Y, Nakagawa K, Kawakami Y and Tsuchiya E: The expression of p73 is increased in lung cancer, independent of p53 gene alteration. Br J Cancer 80: 1623-1629, 1999.
12. Zaika AI, Kovalev S, Marchenko ND and Moll UM: Over-expression of the wild type p73 gene in breast cancer tissues and cell lines. Cancer Res 59: 3257-3263, 1999.
13. Kang M-J, Park B-J, Byun D-S, Park J-I, Kim H-J, Park J-H and Chi S-J: Loss of imprinting and elevated expression of wild-type p73 in human gastric adenocarcinoma. Clin Cancer Res 6: 1767-1771, 2000.
14. Nicholson SA, Okby NT, Khan MA, Welsh JA, McMenamin MG, Travis WD, Jett JR, Tazelaar HD, Trastek V, Pairolero PC, Corn PG, Herman JG, Liotta LA, Caporaso NE and Harris CC: Alterations of p14ARF, p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small cell lung carcinoma. Cancer Res 61: 5636-5643, 2001.
15. Concin N, Becker K, Slade N, Erster S, Mueller-Holzner E, Ulmer H, Daxenbichler G, Zeimet A, Zeillinger R, Marth C and Moll UM: Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res 64: 2449-2460, 2004.
16. Stiewe T, Tuve S, Peter M, Tannapfel A, Elmaagacli AH and Putzer BM: Quantitative TP73 transcript analysis in hepatocellular carcinomas. Clin Cancer Res 10: 626-633, 2004.
17. Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Morita M, Funa K and Yasumoto K: Expression of deltaNp73 predicts poor prognosis in lung cancer. Clin Cancer Res 10: 6905-6911, 2004.
18. Casciano I, Mazzocco K, Boni L, Pagnan G, Banelli B, Allemanni G, Ponzoni M, Tonini GP and Romani M: Expression of ΔNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ 9: 246-251, 2002.
19. Inoue T, Stuart J, Leno R and Maki CG: Nuclear import and exportsignals in control of the p53-related protein p73. J Biol Chem 277: 15053-15060, 2002.
20. Dobbelstein M, Strano S, Roth J and Blandino G: p73-induced apoptosis: a question of compartments and cooperation. Biochem Biophys Res Commun 331: 688-693, 2005.
21. Moll UM, LaQuaglia M, Benard J and Riou G: Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA 92: 4407-4411, 1995.
22. Evangelou K, Bramis J, Peros I, Zacharatos P, Dasiou-Plakida D, Kalogeropoulos N, Asimacopoulos P, Kittas C, Marinos E and Gorgoulis V: Electron microscopy evidence that cytoplasmic localization of the p16(INK4A) 'nuclear' cyclin-dependent kinase inhibitor (CKI) in tumor cells is specific and not an artifact. A study in non-small cell lung carcinomas. Biotech Histochem 79: 5-10 2004.
23. INK4a promoter methylation and altered protein expression in breast fibroadenoma and carcinoma. Int J Cancer 114: 414-421, 2005.
24. Corn PG, Kuerbitz SJ, van Noesel MM, Esteller M, Compitello N, Baylin SB and Herman JG: Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation. Cancer Res 59: 3352-3356, 1999.
25. Kawano S, Miller CW, Gombart AF, Bartram CR, Matsuo Y, Asou H, Sakashita A, Said J, Tatsumi E and Koeffler HP: Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. Blood 94: 1113-1120, 1999.
26. Banelli B, Casciano I and Romani M: Methylation-independent silencing of the p73 gene in neuroblastoma. Oncogene 19: 4553-4556, 2000.
27. Casciano I, Banelli B, Croce M, Allemanni G, Ferrini S, Tonini GP, Ponzoni M and Romani M: Role of methylation in the control of DeltaNp73 expression in neuroblastoma. Cell Death Differ 9: 343-345, 2002.
28. Banelli B, Gelvi I, Di Vinci A, Scaruffi P, Casciano I, Allemanni G, Bonassi S, Tonini GP and Romani M: Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors. Oncogene 24: 5619-5628, 2005.
29. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G and Brown R: CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 65: 8961-8967, 2005.
30. Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996.
31. Sadri R and Hornsby PJ: Rapid analysis of DNA methylation using new restriction enzyme sites created by bisulfite modification. Nucleic Acids Res 24: 5058-5059, 1996.
32. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-458, 1958.
33. Douc-Rasy S, Barrois M, Echeynne M, Kaghad M, Blanc E, Raguenez G, Goldschneider D, Terrier-Lacombe MJ, Hartmann O, Moll U, Caput D and Benard J: DeltaN-p73alpha accumulates in human neuroblastic tumors. Am J Pathol 160: 631-639, 2002.
34. Falini B, Bolli N, Shan J, Martelli MP, Liso A, Pucciarini A, Bigerna B, Pasqualucci L, Mannucci R, Rosati R, Gorello P, Roti DDG, Tiacci E, Cazzaniga G, Biondi A, Schnittger S, Haferlach T, Hiddemann W, Martelli MF, Gu W, Mecucci C and Nicoletti I: Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood 107: 4514-4523, 2006.
35. Bellodi C, Kindle K, Bernassola F, Dinsdale D, Cossarizza A, Melino G, Heery D and Salomoni P: Cytoplasmic function of mutant promyelocytic leukemia (PML) and PML-retinoic acid receptor-alpha. J Biol Chem 281: 14465-14473, 2006.
36. Tannapfel A, Wasner M, Krause K, Geissler F, Katalinic A, Hauss J, Mössner J, Engeland K and Wittekind C: Expression of p73 and its relation to hystopathopology and prognosis in hepatocellular carcinoma. J Natl Cancer Inst 91: 1154-1156, 1999.
37. Tannapfel A, Engeland K, Weinans L, Katalinic A, Hauss J, Mössner J and Wittekind CH: Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver. Br J Cancer 80: 1069-1074, 1999.
38. Dominguez G, Garcia JM, Pena C, Silva J, Garcia V, Martinez L, Maximiano C, Gomez ME, Rivera JA, Garcia-Andrade C and Bonilla F: DeltaTAp73 upregulation correlates with poor prognosis in human tumors: Putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol 24: 805-815, 2006.
39. Bozzetti C, Nizzoli R, Musolino A, Martella EM, Crafa P, Lagrasta CA, Camisa R, Bonati A, Lunghi P and Ardizzoni A: p73 and p53 Pathway in Human Breast Cancers. J Clin Oncol 25: 1451-1453, 2007.
40. Chang MS, Uozaki H, Chong JM, Ushiku T, Sakuma K, Ishikawa S, Hino R, Barua RR, Iwasaki Y, Arai K, Fujii H, Nagai H and Fukayama M: CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus. Clin Cancer Res 12: 2995-3002, 2006.
41. Peng DF, Kanai Y, Sawada M, Ushijima S, Hiraoka N, Kitazawa S and Hirohashi S: DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas. Carcinogenesis 27: 1160-1168, 2006.